三氧化二砷联合LD-HA治疗MDS及难治性急性非淋巴细胞白血病的疗效观察

Clinical Analysis of 40 Patients with As_2O_3 and Low Dsoe Homoharringtorine-cytarabine in the Treatment of Myelodysplastic Syndrome and Refractory or Released Acute Myeloid Leukemia

目的回顾性分析三氧化二砷联合LD-HA治疗MDS及难治性白血病的疗效及不良反应。方法应用三氧化二砷（10 mg/d,1~5 d,8~12 d）＋LD-H A（高三尖杉酯碱2 mg/d,阿糖胞苷25 mg、2次/天,D1~14治疗。WBC〈1.0×10^9/L时使用粒细胞集落刺激因子（G-CSF）5 g/（kg？d）直至WBC〉1.0×10^9/L。结果 1个疗程的总有效率达67.5%,其中CR 24例（60%）,PR 3例（7.5%）,NR13例（32.5%）。复发难治AML和MDS患者1个疗程的CR率分别达45.5%（5/11）、65.5%（19/29）。结论三氧化二砷联合LD-HA能够有效的治疗MDS及难治性急性非淋巴细胞白血病。

Objective To observe the therapeutic outcome and adversere action of As2O3 and low-dose homoharringtonine-cytarabine（LD-HA）in the treatment of myelodysplastic syndrome and refractory or released acute myeloid leukemia patients. Methods All the patients was treated with As203（10 mg/d, 1-5 d, 8-12 d） and LD-RA： homohah-nigtonnie（H）2 mg/d and Ara-C 25 mg, per 12 h, 1-14 d. Granulocyte colony-stimulating factor were used when white blood cells count WBC〈1.0× 10^9/L.Results After one course of induction therapy, the complete remission （CR）rates of myelodysplastic syndrome and refractory or released acute myeloid leukemia were 65.5% and 45,5% respectively, There were no great side effect occour during the treatment, Conclusion As2O3 together with LD-HA schema offers a higher CR rate and has fewer adversere action in the treatment of myelodysplastic syndrome and refractory or released acute myeloid leukemia patients.